Call Us Now: +32 460 225 693
Non-skin contact wearable device amofit S to begin shipping next month

Non-skin contact wearable device amofit S to begin shipping next month

Amofit S Uses Patented Neuromodulation Technology to Improve Sleep and Reduce Stress Level

Delivery status. ‘Amofit S’ units are being assembled and shipped in real time

February 21, 2022. Amo Lab launches an Indiegogo campaign for its newest innovation, ‘amofit S’, the world’s first non-skin contact wearable device which aims to improve overall human body performance and help people with anxiety, insomnia, and chronic disease related to problems in the vagus nerve.

‘Amofit S’ is a long-awaited follow-up to the company’s first-generation product, AMO+, which was released on a well-known Korean crowdfunding platform, ‘Wadiz’, in 2019. With over 2,249 supporters and overwhelmingly positive responses from the backers, the Amo Lab team has been committed to the mission of advancing the technology to ensure the ultimate combination of performance and safety.

“There are various chronic diseases that are difficult to be solved with modern medical technology. Among these, the ‘invisible’ diseases such as chronic stress, anxiety, and lack of sleep negatively affect and disrupt our immune system and increase the risk of developing or worsening the diseases,” says Min Kyu. “The amofit S provides an easy solution to the problems that are fundamentally difficult to solve in the modern healthcare system, such as insomnia, stress, and nervous disorders.”

Four main components of a healthy body and a clear mind include regular exercise, healthy diets, good sleep, and low-stress levels. Our innovation is going to drastically improve two of these factors ─ better sleep and lower stress — along with many additional benefits that fundamentally improve the human body.

How does amofit S work?

‘amofit S’ operates with the help of AMO Lab’s proprietary neuromodulation technology, cVES (cervicothoracic vagus electromagnetic stimulation), which targets the vagus nerve in the human’s autonomic nervous system. 

With a mild intensity similar to the innate magnetic field generated by the human body itself, the electromagnetic signal passes through the skin, muscles, and bones without any interference. It then is transmitted to the vagus nerve in the chest area. This signal regulates the vagal tone and activates the parasympathetic nervous system. 

The procedure reduces anxiety, stress, and sleep problems, boosts healthy aging, and restores the balance of the body. As a result of stimulating alpha brain waves and restoring internal balance through homeostasis, users will also notice major improvements in memory and creativity.

‘amofit S’ provides two healing modes.

  • CALM mode – Increase the vagal tone and activates the parasympathetic nervous system to improve sleep, stress, and anxiety and correct the body’s internal balance, as well as help with chronic diseases related to problems in the vagus nerve and the autonomic nervous system. 

  • FOCUS mode – Enhances memory and creativity by promoting the generation of alpha brain waves and restores the internal balance through homeostatic autoregulation.

Approved by various testings 

To ensure the safety of the technology, ‘amofit S’ has undergone several tests including a clinical trial on HRV, conducted at KRISS (Korea Research Institute of Standards and Science). The experiment revealed a 275% increase in the activities of the parasympathetic nerves by analyzing EEG (Electroencephalography), ECG (Electrocardiogram), and melatonin hormone measurements.

“Heart rate variability (HRV) functions as a biomarker in health and disease. It is also the best biomarker to track longevity of the human. The initial goal of our team of scientists is to develop bioelectronic medicine for chronic pain with vagus nerve stimulation (VNS) technology,” adds Min Kyu, the CEO of the company. 

In addition, ‘amofit S’ has also been tested against the US FCC, European CE, and Korean KC directives and conforms to safety standards. (You can access our available certifications and scientific papers here).

AMO+ (the ancestor of Amofit S) is currently holding an excellent user score of 4,5/5 based on the experience of 2,249 backers.

Appearance and functionality 

Amofit S is the smallest device of its kind available on the market. Due to the miniature size and the neutral color variations (light grey/dark grey), it can be worn over clothing using a necklace string or by clipping the product to your collar without any inconvenience. In addition, a non-contact neurostimulation technology ensures that the device is also effective from a distance of up to 9 inches.

The device operates with the help of touch buttons. Press on the logo area for 3 seconds to turn on the device. A further press on the mode selection area will switch the modes from ‘Calm’ to ‘Focus’ and vice versa. Based on our clinical studies and the reviews from the backers, It will take only 3 days (30-minutes sessions each) to already experience noticeable benefits.


‘Amofit S’ is currently in its shipping stage and is available for backers on Indiegogo with a starting price of $199.

About the team

‘Amofit S’ has been brought to reality by a group of young scientists holding bachelor’s degrees in biology, chemistry, and computer engineering. Initially formed in 2012 at the University of Illinois at Urbana-Champaign, the small group of researchers has eventually grown into a biotechnology company currently known as Amo Lab with branches in South Korea and the United States. 

The Amo Lab team completed the cVES technology in 2017 based on the rapid biomarker changes in HRV (heart rate variability) discovered in a clinical study back in 2013. To date, the company has developed more than 30 treatment protocols.

The scientific paper on the topic “Physiological evaluation of Non-invasive wearable vagus nerve stimulation device” has been conducted by the Amo Lab research team and published in “Springer Nature” in July 2019.

Read More

Leave a Reply

Your email address will not be published.